|
Renalytix PLC - London-based diagnostics company focused on kidney health - Says US federal Medicare administrative contractor, National Government Services, starts paying for use of KidneyIntelX, a test that predicts which adult patients with type 2 diabetes and with chronic kidney disease are at risk from decline in kidney function. Renalytix will receive $950 per reportable result. Medicare patient samples are being processed in the company's New York laboratory.
Current stock price: 49.70 pence, down 0.6% on Tuesday
12-month change: down 94%
Copyright 2022 Alliance News Limited. All Rights Reserved.
|
